Ahmadpour Forouzan, Kouchak Mehran, Miri Mir Mohammad, Salarian Sara, Shojaei Seyedpouzhia, Ramezanzadeh Kiana, Rezapour Paria, Sistanizad Mohammad
Department of Clinical Pharmacy, Faculty of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Department of Critical Care Medicine, Imam Hossein Medical and Educational Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Iran J Pharm Res. 2020 Spring;19(2):264-273. doi: 10.22037/ijpr.2019.112452.13766.
Disease-related malnutrition of neurocritical illness harms its treatment, which increases the mortality rate. The aim of this study was evaluating the effect of a high protein diet on the dietary factors, clinical outcome, and mortality rate of neurocritical patients. In a randomized controlled trial, 15 neurocritical patients were recruited in each group. The patients in the intervention and control groups received high protein and conventional protein regimens, respectively. The Clinical Extended Glasgow Outcome Scale (GOSE) measured at one, two, and three months later. Acute Physiology and Chronic Health Evaluation II (APACHE-II) score, Glasgow Coma Scale, the serum level of transthyretin (TTR) on the first, 3 and fifth days of admission, and nitrogen balance (NB) at the baseline and fifth day of the study were recorded. Thirty patients, 15 in each group, entered into the study. There was no statistically significant difference in the baseline characteristics of the patients between the two groups of the study. The 28-days-mortality rate in the intervention and control group were 33.3% (n = 5) and 73.3% (n = 11), -value = 0.034, respectively. The GOSE scores were higher in the patients who received a high protein diet, and lower in the patients with lower baseline TTR, higher APACHE-II score, older age, and a baseline negative nitrogen balance. The high protein diet may decrease the mortality rate, and improve the clinical outcome of neurocritical patients. The baseline TTR level, APACHE II score, and NB are prognostic factors for the prediction of the GOSE in neurocritical patients.
神经危重症相关的疾病性营养不良会对其治疗产生不利影响,进而增加死亡率。本研究的目的是评估高蛋白饮食对神经危重症患者饮食因素、临床结局和死亡率的影响。在一项随机对照试验中,每组招募了15名神经危重症患者。干预组和对照组患者分别接受高蛋白和常规蛋白方案。在1个月、2个月和3个月后测量临床扩展格拉斯哥预后量表(GOSE)。记录入院第1天、第3天和第5天的急性生理与慢性健康状况评分II(APACHE-II)、格拉斯哥昏迷量表、转甲状腺素蛋白(TTR)血清水平,以及研究基线和第5天的氮平衡(NB)。30名患者(每组15名)进入研究。两组患者的基线特征在统计学上无显著差异。干预组和对照组的28天死亡率分别为33.3%(n = 5)和73.3%(n = 11),P值 = 0.034。接受高蛋白饮食的患者GOSE评分较高,而基线TTR较低、APACHE-II评分较高、年龄较大且基线负氮平衡的患者GOSE评分较低。高蛋白饮食可能会降低神经危重症患者的死亡率,并改善其临床结局。基线TTR水平、APACHE II评分和NB是预测神经危重症患者GOSE的预后因素。